LIPOSARCOMA

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…

This early-phase trial is testing whether the drug abemaciclib, when given with radiation therapy before surgery, can safely shrink high-risk retroperitoneal liposarcomas. About 18 adults with this rare cancer will receive the combination to find the best dose and check for side …

This study is for people with a rare, high-risk cancer called retroperitoneal sarcoma. It compares two approaches: getting chemotherapy before surgery versus surgery alone. The goal is to see if the chemo-first approach helps prevent the cancer from coming back. About 250 partici…

This study tests whether combining two drugs, mirdametinib and palbociclib, can safely slow or stop advanced liposarcoma (a rare soft-tissue cancer). About 54 adults with liposarcoma that has spread or cannot be removed will receive different doses to find the best one. The main …

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …

This early-phase trial tests a new immunotherapy called CARE T cells in children and young adults with solid tumors that have returned or not responded to standard treatment. The cells are taken from the patient, genetically modified to recognize a protein (GPC3) found on many so…

This early-phase trial tests a new treatment called attIL12-TIL for people with advanced or metastatic soft tissue and bone sarcoma. The therapy uses a patient's own tumor-fighting immune cells, modified to better target and attack cancer. The study first finds a safe dose, then …

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells, which are genetically modified in the lab to recognize and attack cancer cells…

This study tests whether a higher dose of proton radiation can better control inoperable soft tissue sarcomas without increasing side effects. Forty adults with these rare tumors will receive targeted radiation over 4 weeks. Researchers will also look at blood and imaging markers…

This study tests whether a personalized 3-week course of proton radiation before surgery for soft tissue sarcoma can reduce long-term side effects compared to standard X-ray radiation. About 110 adults in Norway will receive either proton or X-ray therapy, chosen individually for…

This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…

This study investigates whether fragments of tumor DNA circulating in the blood can be used to detect and monitor soft tissue sarcoma. Researchers will collect blood and tumor tissue samples from 40 adults with high-risk sarcomas to see if this DNA can serve as a biomarker for ca…

This study is collecting tissue samples and medical data from 800 high-risk sarcoma patients to develop personalized treatment approaches. Researchers will analyze genetic and protein profiles to better predict which patients benefit from chemotherapy before surgery. The goal is …